anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a novel randomized crossover, double-blinded pilot study that aims to investigate the effects of different omega-3 fatty acids, namely EPA and DHA, on lipoprotein metabolism. Subjects will be unblinded for performance of measurements after they complete the study. Subjects will receive EPA or DHA supplements for approximately 6 weeks with a wash out period of 8 weeks between the two arms of the study. The study consists of 4 outpatient visits when laboratory or research samples and CAVI tests will be performed. A 7-day food diary, pill count, and red cell membrane n-3 levels will be monitored to assess compliance.

Serum cholesterol is transported by lipoproteins, such as VLDL, LDL and HDL, which vary in their relationship to cardiovascular risk. LDL is proatherogenic, whereas HDL is cardio-protective. Fish oil supplementation, such as EPA and DHA, has been shown to reduce triglycerides. EPA supplementation has also been shown to lower LDL-C, whereas DHA can raise both LDL-C and HDL-C. These differential effects on lipoproteins may alter the cardiovascular protection afforded by fish oil supplementation. This study will test the hypothesis that EPA and DHA may differ in their LDL-C lowering ability because of differences in how they modulate plasma PCSK9 levels, which is a major determinant of LDL-C levels. In addition, we will assess other parameters related to lipoprotein composition and function that may impact the cardioprotective effect of EPA and DHA. Other reported beneficial effects of omega-3 fatty acid supplementation, such as decreased platelet coagulability, markers of inflammation and changes in guy microbiota, will also be monitored.
The global impact of the COVID-19 pandemic has been substantial. Emerging evidence underscores a strong clinical connection between COVID-19 and sepsis. Numerous studies have identified the unfolded protein response (UPR) pathway as a crucial pathogenic pathway for both COVID-19 and sepsis, but it remains to be investigated whether this signaling pathway operates as a common pathogenic mechanism for both COVID-19 and sepsis. In this study, single-cell RNA-seq data and transcriptome data for COVID-19 and sepsis cases were downloaded from GEO (Gene Expression Omnibus). By analyzing the single-cell transcriptome data, we identified B cells as the critical cell subset and the UPR pathway as the critical signaling pathway. Based on the transcriptome data, a machine learning diagnostic model was then constructed using the interleaved genes of B-cell-related and UPR-pathway-related genes. We validated the diagnostic model using both internal and external datasets and found the accuracy and stability of this model to be extremely strong. Even after integrating our algorithmic model with the patient's clinical status, it continued to yield identical results, further emphasizing the reliability of this model. This study provides a novel molecular perspective on the pathogenesis of sepsis and COVID-19 at the single-cell level and suggests that these two diseases may share a common mechanism.
PURPOSE:To provide a plaster having stickiness to enable the direct application to the skin and elasticity to protect the skin, by coating a carrier with a mixture composed of a specific polyester elastomer, a tackifier component, an oil and fat or a higher fatty acid, and a drug component. CONSTITUTION:The objective plaster can be prepared by coating a carrier with a mixture containing, as essential components, (i) 100pts.(wt.) of a polyester elastomer composed of a recurring long-chain ester such as polytetramethylene ether terephthalate and a recurring short-chain ester unit such as polybutylene terephthalate, and having a general structure of A-B (A is soft polymer segment and B is hard polymer segment; and weight ratio A/B is preferably 40-70/60- 30), (ii) 50-400pts. of a tackifier component (e.g. rosin, petroleum resin, etc.), (iii) 20-300pts. of an oil and fat or a higher fatty acid (preferably having a boiling point higher than the melting point of the above elastomer), and (iv) a drug component e.g. an anti-inflammatory analgesic agent such as emthyl salicylate.
This study explores the role of the transcription factor FOXM1 in the initiation and progression of oesophageal squamous cell carcinoma (ESCC). Our findings reveal that FOXM1 is highly expressed in ESCC and correlates with the prognosis of the disease. The relationship between FOXM1 and asparagine synthetase (ASNS) is investigated, and the study demonstrates that FOXM1 activates ASNS, impacting the tumour stemness of ESCC. In this study, we reveal the association between FOXM1 and ESCC development, as well as FOXM1's promotion of migration and proliferation in ESCC cells. The study also highlights FOXM1's regulation of ASNS transcription and the functional role of ASNS in ESCC metastasis and growth. Furthermore, the study explores the impact of FOXM1 and ASNS on ESCC stemness and their potential implications for chemotherapy resistance.
PROBLEM TO BE SOLVED: To provide an anti-c-Met antibody inhibiting activation of both ligand-dependent and independent c-Met, more specifically inhibiting dimerization of c-Met.SOLUTION: A new antibody comprises a heavy chain comprising CDR-H1, CDR-H2 and CDR-H3 comprising an amino acid having a specific sequence and a light chain comprising CDR-L1, CDR-L2 and CDR-L3 comprising an amino acid having a specific sequence, where the antibody is capable of specifically bonding to a human c-Met receptor and/or of specifically inhibiting tyrosine kinase activity of the receptor. A mouse hybridoma secretes the antibody. A monoclonal antibody is originated from mouse, chimera and human. An amino acid and a nucleic acid sequence code these antibodies. Such an antibody is for producing an agent for the purpose of treatment of a cancer. A composition, a diagnostic process and a kit comprise such an antibody.
Prepn. of a hyperglycaemic factor which includes a general glycogenolysio and glycosuric elimination, by extracting red bone marrow from flat bones which have had the bony exterior removed. The hyperglycaemic factor does not alter the functions of the blood and heart but has a beneficial effect on them in physiological doses. The factor is heat-stable and is a protein. After use blood sugar levels return to normal. Typically, red bone marrow frozen at low temp. is minced into acetone, supernatant is decanted from boney particles and filtered. The acetone paste is extracted with hot 0.1 m phosphate buffer at pH 6.8 at 65 degrees C for 1 h and the extract is purified by adsorption of impurities on calcium phospate.
BACKGROUND: Chronic kidney disease affects 10% of the world population, and it is associated with progression to end-stage kidney disease and increased morbidity and mortality. The advent of multi-omics technologies has expanded our knowledge on the complexity of kidney diseases, revealing their frequent genetic etiology, particularly in children and young subjects. Genetic heterogeneity and drug screening require patient-derived disease models to establish a correct diagnosis and evaluate new potential treatments and outcomes.
SUMMARY: Patient-derived renal progenitors can be isolated from urine to set up proper disease modeling. This strategy allows to make diagnosis of genetic kidney disease in patients carrying unknown significance variants or uncover variants missed from peripheral blood analysis. Furthermore, urinary-derived tubuloids obtained from renal progenitors of patients appear to be potentially valuable for modeling kidney diseases to test ex vivo treatment efficacy or to develop new therapeutic approaches. Finally, renal progenitors derived from urine can provide insights into acute kidney injury and predict kidney function recovery and outcome.
KEY MESSAGES: Renal progenitors derived from urine are a promising new noninvasive and easy-to-handle tool, which improves the rate of diagnosis and the therapeutic choice, paving the way toward a personalized healthcare.
Two markers on Chromosome 2 of chickpea (Cicer arietinum ) are reportedly associated with resistance to race 4 Fusarium wilt, and are frequently used in breeding. However, the genes in this region that actually confer wilt resistance are unknown. We aimed to characterise them using both in silico approaches and marker trait association (MTA) analysis. Of the 225 protein-encoding genes in this region, 51 showed significant differential expression in two contrasting chickpea genotypes under wilt, with potential involvement in stress response. From a diverse set of 244 chickpea genotypes, two sets of 40 resistant and 40 susceptible genotypes were selected based on disease incidence and amplification pattern of the TA59 marker. All cultivars were further genotyped with 1238 single nucleotide polymorphisms (SNPs) specific to the 51 genes; only seven SNPs were significantly correlated with disease. SNP Ca2_24099002, specific to the LOC101498008 (Transmembrane protein 87A) gene, accounted for the highest phenotypic variance for disease incidence at 16.30%, whereas SNPs Ca2_25166118 and Ca2_27029215, specific to the LOC101494644 (β-glucosidase BoGH3B-like) and LOC101505289 (Putative tRNA pseudouridine synthase) genes, explained 10.51% and 10.50% of the variation, respectively, in the sets with contrasting disease susceptibility. Together with the TA59 and TR19 markers, these SNPs can be used in a chickpea breeding scheme to develop wilt resistance.
PROBLEM TO BE SOLVED: To provide a cosmetic material having a sufficient coating capacity while looked transparent, and making the skin look smooth while making pores, liver spots, and freckles inconspicuous. SOLUTION: When the amount of a surface reflection light and a powder layer reflection light is measured under a light receiving condition of 2 deg. visual field with C light using a bending spectrometric colorimeter with an S polarizing plate or a P polarizing plate each on the incidental light and the receiving light sides on a sample prepared by uniformly coating a 10 mg mixture of a composite inorganic powder, a talk, and squalane (47:47: 6 by weight ratio) on a 10 cm×5 cm part of an artificial skin, this composite inorganic powder shows the difference of 7-15 in the amount of a surface reflection light measured under a condition of an incidental angle of 45 deg. and a receiving light angle of 45 deg., and that under a condition of an incidental angle of 45 deg. and a receiving light angle of 0 deg., respectively, and the difference of -3-3 in the amount of the surface reflection light and the powder layer reflection light measured under a condition of an incidental angle of 45 deg. and a receiving light angle of 0 deg., and this cosmetic material contains the composite inorganic powder.
(see CONTRAINDICATIONS)

Cetrotide® is contraindicated in pregnant women.

When administered to rats for the first seven days of pregnancy, cetrorelix acetate did not affect the development of the implanted conceptus at doses up to 38 μg/kg (approximately 1 times the recommended human therapeutic dose based on body surface area). However, a dose of 139 μg/kg (approximately 4 times the human dose) resulted in a resorption rate and a postimplantation loss of 100%. When administered from day 6 to near term to pregnant rats and rabbits, very early resorptions and total implantation losses were seen in rats at doses from 4.6 μg/kg (0.2 times the human dose) and in rabbits at doses from 6.8 μg/kg (0.4 times the human dose). In animals that maintained their pregnancy, there was no increase in the incidence of fetal abnormalities.

The fetal resorption observed in animals is a logical consequence of the alteration in hormonal levels effected by the antigonadotrophic properties of Cetrotide®, which could result in fetal loss in humans as well. Therefore, this drug should not be used in pregnant women.
The VT will be kept at 6 mL/kg of PBW. If the plateau pressure threshold is reached (30 cm H2O), the VT will be decreased down to a minimal value of 4 mL/kg of PBW.
Students without known disease, between 14 and 18 years from the "Lic. Adolfo Lopez Mateos" Preparatory school of the Autonomous University of the State of Mexico (UAEMex).
Patients receive nilotinib hydrochloride monohydrate PO BID on days 1-28 and paclitaxel IV over 1 hour on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI during screening or cycle 1 day 1, every 2 cycles for 1 year, every 3 cycles for patients on study for more than 1 year, and every 4 cycles for patients on study for more than 3 years and may also undergo CT or MRI during follow-up every 3 months for 2 years and then every 6 months for 1 year if clinically indicated. Patients also undergo collection of blood samples at baseline, cycle 2 day 1, and optionally at progression as well as tumor biopsy at baseline and optionally at progression.
Participants wear Fitbit, receive home-based DVD containing instructions to warm-up and cool-down, and brisk walk 30 minutes per day 5 days a week in order to achieve the 150 minutes per week of moderate intensity exercise. Participants also receive resistance training by watching the illustration video and completing 6 total blocks of 2-week per block exercise using the Thera-BandR exercise bands.
The invention relates to formulations of single domain antigen binding molecules, e.g. nanobody molecules, in particular formulations of TNF-binding nanobody molecules. The single domain antigen binding molecules can include one or more single binding domains that interact with, e.g. bind to, one or more target proteins. The formulations are useful, e.g., as pharmaceutical formulations. Method of preparing, and using the formulations described herein, to treat, e.g., TNF-associated disorders, are also disclosed.
PURPOSE:An antilipemic agent, containing trimethylsteroid as a main component, and capable of exhibiting cholesterol reducing action in blood equal to that of a vegetable sterol, e.g. beta-sitosterol. CONSTITUTION:An antilipemic agent containing trimethylsteroid, particularly preferably cycloartenol and 24-methylenecycloartanol, as a main component. A carrier or adjuvant is added to the above-mentioned compounds and formulated into an agent for the oral administration, e.g. a tablet, powder, capsule or syrup, etc. The daily dose thereof is 0.2-15g, preferably 0.5-5g for adults.
NEW MATERIAL:A substance selected from NF-86I, NF-86II, NPF-86IA, NPF-86 IB, NPF-86II and NPF-86IIB. The NF-86I has the following properties. Appearance, pale yellowish brown powder; melting point, no definite melting point; elemental analysis, C 56.3%, H 4.61%, N <=0.2%, ash <=0.3%; molecular weight, 1,000-10,000; solubility, soluble in water and methanol, insoluble in hexane, etc.; color reaction, positive to ferric chloride reaction and negative to ninhydrin reaction, etc. USE:A carcinostatic agent. It has extremely low toxicity compared with natural substance and can be administered in large quantities. PREPARATION:Betel nut used as a raw material is defatted and extracted with methanol. The extract liquid is concentrated to dryness, suspended in water and filtered. A fraction soluble in a non-hydrophilic organic solvent is removed from the filtrate and has remaining aqueous layer is successively dialyzed with a dialysis tube having a critical molecular weight of 1,000 and then with a dialysis tube having a critical molecular weight of 10,000. The obtained active fraction is separated and purified by high-performance liquid chromatography.
BACKGROUND: Chronic pancreatitis (CP) is characterized by debilitating pain which affects patients' quality of life. Early surgical intervention has been shown to mitigate pain and prevent a decline in quality of life. The present study evaluated the impact of bile duct and duodenum preserving pancreatic head resection (BDPPHR), an innovative technique, on pain relief, functional outcomes, postoperative morbidity, and mortality in patients with CP.
METHODS: Between March 2019 and July 2022, a total of 37 patients underwent bile duct and duodenum preserving pancreatic head resection (BDPPHR) for pain relief in patients with CP. Post-operative outcomes were assessed by Izbicki pain score, exocrine insufficiency, endocrine insufficiency, and return to work. The safety of the surgical procedure was determined by evaluation of postoperative morbidity and mortality as per Clavien-Dindo scores.
RESULTS: BDPPHR showed a significant reduction in Izbicki pain scores with 30 (81 %) patients experiencing complete or partial pain relief up to 18 months of follow up. 32(86 %) patients ceased narcotic use by the end of the 18-month follow-up period. 33 (89 %) patients were able to resume regular work at the end of 18 months. There were no significant alterations in both exocrine and endocrine statuses post-surgery. The median duration of hospital stay was 4.5 days (3-11). Major complications occurred in 2 (5 %) patients. There was no post-operative mortality.
CONCLUSION: BDPPHR is a novel and safe technique of near total head resection which results in very good pain relief in 81 % of patients.
In the three fixed dose groups (10 mg/kg, 15 mg/kg and 20 mg/kg), when a certain dose group meets the condition of increasing the dose to the higher dose (after the DLT observation period for the last subject in the dose group), the second phase of the dose expansion study for this dose group can be carried out. Each dose group includes 6 patients with HER2-positive advanced solid tumors who have failed the standard treatment, and the interval between enrollment is determined by the investigator.
BACKGROUND AND PURPOSE: Excessive fibrogenesis is associated with adverse cardiac remodelling and heart failure. The myofibroblast, primarily derived from resident fibroblast, is the effector cell type in cardiac fibrosis. Megakaryocytic leukaemia 1 (MKL1) is considered the master regulator of fibroblast-myofibroblast transition (FMyT). The underlying transcriptional mechanism is not completely understood. Our goal was to identify novel transcriptional targets of MKL1 that might regulate FMyT and contribute to cardiac fibrosis.
EXPERIMENTAL APPROACH: RNA sequencing (RNA-seq) performed in primary cardiac fibroblasts identified insulin-like growth factor binding protein 5 (IGFBP5) as one of the genes most significantly up-regulated by constitutively active (CA) MKL1 over-expression. IGFBP5 expression was detected in heart failure tissues using RT-qPCR and western blots.
KEY RESULTS: Once activated, IGFBP5 translocated to the nucleus to elicit a pro-FMyT transcriptional programme. Consistently, IGFBP5 knockdown blocked FMyT in vitro and dampened cardiac fibrosis in mice. Of interest, IGFBP5 interacted with nuclear factor of activated T-cell 4 (NFAT4) to stimulate the transcription of microfibril-associated protein 5 (MFAP5). MFAP5 contributed to FMyT and cardiac fibrosis by enabling sterol response element binding protein 2 (SREBP2)-dependent cholesterol synthesis.
CONCLUSIONS AND IMPLICATIONS: Our data unveil a previously unrecognized transcriptional cascade, initiated by IGFBP5, that promotes FMyT and cardiac fibrosis. Screening for small-molecule compounds that target this axis could yield potential therapeutics against adverse cardiac remodelling.
Sham cognitive rehabilitation will consist of basic internet searches and learning to use a computer, and aerobic exercises will focus primarily on improving cardio-respiratory fitness using a recumbent bike. Sessions will take place twice a week for 12 weeks.
Subarachnoid hemorrhage (SAH) is the deadliest form of hemorrhagic stroke; however, effective therapies are still lacking. Perfluorocarbons (PFCs) are lipid emulsion particles with great flexibility and their much smaller size as compared to red blood cells (RBCs) allows them to flow more efficiently within the blood circulation. Due to their ability to carry oxygen, a specific PFC-based emulsion, PFC-Oxygent, has been used as a blood substitute; however, its role in cerebral blood flow regulation is unknown. Adult C57BL/6 wildtype male mice were subjected to an endovascular perforation model of SAH followed by an intravenous (i.v.) injection of 9 ml/kg PFC-Oxygent or no treatment at 5 h after SAH. At 48 h after SAH, functional and anatomical outcomes were assessed. We found that SAH resulted in significant neurologic and motor deficits which were prevented by PFC-Oxygent treatment. We found that SAH-induced vasospasm, reduced RBC deformability, and augmented endothelial dysfunction were also restricted by PFC-Oxygent treatment. Moreover, mitochondrial activity and fusion proteins were also markedly decreased as assessed by oxidative phosphorylation (OXPHOS) after SAH. Interestingly, PFC-Oxygent treatment brought the mitochondrial activity close to the basal level. Moreover, SAH attenuated the level of phosphorylated AMP-activated protein kinase (pAMPK), whereas PFC treatment improved pAMPK levels. These data show the beneficial effects of PFC-Oxygent in limiting the severity of SAH. Further studies are needed to fully understand the mechanism through which PFC-Oxygent exerts its beneficial effects in limiting SAH severity.
The foliage and stems of plant species from the family Rosacea, genus  Prunus,  yield natural pesticides when macerated. Hydrodistillation of macerated plant biomass yields a concentrated solution of organic volatile compounds that act synergistically as a natural pesticide, and as provided herein, also act synergistically as antimicrobial compounds. Volatile compounds liberated from  Prunus  biomass include 2-propanol, hexanal, trans-2-hexenal, 1-hexanol, cis-3-hexenol, mandelonitrile, benzoic acid, benzaldehyde, benzyl alcohol, hydrocyanic acid and others. These compounds may be removed from the distillate and reformulated to form a standard concentrated solution, with benzaldehyde, mandelonitrile and hydrogen cyanide being the major components. Provided herein are methods of using these pesticides as a broad-spectrum bactericide. Components of the extract may act alone or synergistically to control both gram positive and gram negative genera of bacteria.
This is a double-blind, randomized, multiple dose study in male and female adult subjects with schizophrenia. Subjects will undergo structural magnetic resonance abdominal imaging (MRI) scans as well as hyperinsulinemic euglycemic clamp (HEC) also known as "glucose clamp", after the check-in and towards the end of the treatment phase. Subjects will be randomized to SEP-363856 or their prior antipsychotic (PA). Subjects randomized to SEP-363856 will undergo blinded wash out of their PA, subsequent SEP-363856 blinded titration and 15 day of well tolerated SEP-363856 exposure. Subjects randomized to their prior antipsychotic (PA), will undergo pseudo PA washout, followed by pseudo-titration and 15 day of well tolerated PA exposure. Subjects will be discharged after subject is stable. All subjects will return to the clinic 7 + 2 days post discharge for follow-up assessments.